Literature DB >> 33521127

Prognostic Significance of Preoperative Fibrinogen-to-Prealbumin Ratio in Patients with Stage I-III Colorectal Cancer Undergoing Surgical Resection: A Retrospective Cohort Study.

Shizhen Huang1, Guanghui Yuan1, Shuangyi Tang2, Jialiang Gan1.   

Abstract

BACKGROUND: The objective of this study was to explore the role of preoperative fibrinogen-to-prealbumin ratio (FPR) in evaluating the prognosis of patients with stage I-III colorectal cancer (CRC).
METHODS: This retrospective study enrolled 584 stage I-III CRC patients undergoing surgical resection. Logistic regression analysis was used to explore the correlation between FPR and postoperative complications. The Kaplan-Meier curve and Cox proportional hazards model were used to identify the prognostic factors. The nomograms were constructed based on the prognostic factors. The concordance index and calibration curve were used to determine the accuracy of the nomograms. Time-dependent receiver operating characteristic was used to compare the predictive prognostic efficacy of nomograms and TNM stage.
RESULTS: FPR was determined to be an independent factor affecting postoperative complications. Patients with a low-FPR had a significantly better prognosis than those with a high-FPR (disease-free survival, p = 0.028; overall survival, p = 0.027), especially patients with stage I CRC (disease-free survival, p = 0.015; overall survival, p = 0.017). The Cox proportional hazards model identified FPR as an independent poor prognostic factor of disease-free survival (hazard ratio (HR) = 1.459, 95% confidence interval (CI) = 1.074-1.954, p = 0.011) and overall survival (HR = 1.405, 95% CI = 1.034-1.909, p = 0.030). The prognostic nomograms had good accuracy and were superior to the traditional TNM stage.
CONCLUSIONS: FPR is a potential indicator for predicting short- and long-term prognosis of stage I-III CRC patients undergoing surgical resection.
Copyright © 2021 Hailun Xie et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33521127      PMCID: PMC7817313          DOI: 10.1155/2021/3905353

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  40 in total

1.  Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma.

Authors:  Jun Obata; Nobuyuki Tanaka; Ryuichi Mizuno; Kent Kanao; Shuji Mikami; Kazuhiro Matsumoto; Takeo Kosaka; Eiji Kikuchi; Masahiro Jinzaki; Mototsugu Oya
Journal:  BJU Int       Date:  2016-02-19       Impact factor: 5.588

2.  Prealbumin and lymphocyte-based prognostic score, a new tool for predicting long-term survival after curative resection of stage II/III gastric cancer.

Authors:  Qian Shen; Wu Liu; Hu Quan; Shuguang Pan; Shuang Li; Tiejun Zhou; Yongzhong Ouyang; Hua Xiao
Journal:  Br J Nutr       Date:  2018-10-29       Impact factor: 3.718

3.  A NOVEL PROGNOSTIC INDEX IN PATIENTS WITH RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: FIBRINOGEN/PREALBUMIN RATIO.

Authors:  Ji-Feng Feng; Liang Wang; You-Hua Jiang; Xun Yang
Journal:  Rev Invest Clin       Date:  2020       Impact factor: 1.451

4.  Prognostic role of Glasgow prognostic score in patients with colorectal cancer: evidence from population studies.

Authors:  Yangyang Liu; Xingkang He; Jie Pan; Shujie Chen; Liangjing Wang
Journal:  Sci Rep       Date:  2017-07-21       Impact factor: 4.379

5.  Prognostic value of a novel FPR biomarker in patients with surgical stage II and III gastric cancer.

Authors:  Jing Zhang; Shu-Qi Li; Zhi-Hua Liao; Yu-Huan Jiang; Qing-Gen Chen; Bo Huang; Jing Liu; Yan-Mei Xu; Jin Lin; Hou-Qun Ying; Xiao-Zhong Wang
Journal:  Oncotarget       Date:  2017-09-06

6.  Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy.

Authors:  Jiwei Huang; Yanqing Wang; Yichu Yuan; YongHui Chen; Wen Kong; Haige Chen; Jin Zhang; Yiran Huang
Journal:  Oncotarget       Date:  2017-05-30

Review 7.  Microbiota, Inflammation and Colorectal Cancer.

Authors:  Cécily Lucas; Nicolas Barnich; Hang Thi Thu Nguyen
Journal:  Int J Mol Sci       Date:  2017-06-20       Impact factor: 5.923

8.  Computed Tomography-Determined Sarcopenia Is a Useful Imaging Biomarker for Predicting Postoperative Outcomes in Elderly Colorectal Cancer Patients.

Authors:  Hailun Xie; Yizhen Gong; Jiaan Kuang; Ling Yan; Guotian Ruan; Shuangyi Tang; Feng Gao; Jialiang Gan
Journal:  Cancer Res Treat       Date:  2020-04-17       Impact factor: 4.679

9.  The Value of Geriatric Nutritional Risk Index in Evaluating Postoperative Complication Risk and Long-Term Prognosis in Elderly Colorectal Cancer Patients.

Authors:  Shuangyi Tang; Hailun Xie; Jiaan Kuang; Feng Gao; Jialiang Gan; Hesheng Ou
Journal:  Cancer Manag Res       Date:  2020-01-09       Impact factor: 3.989

10.  Preoperative circulating FPR and CCF score are promising biomarkers for predicting clinical outcome of stage II-III colorectal cancer patients.

Authors:  Fan Sun; Hong-Xin Peng; Qiu-Fang Gao; Shu-Qi Li; Jing Zhang; Qing-Gen Chen; Yu-Huan Jiang; Lei Zhang; Xiao-Zhong Wang; Hou-Qun Ying
Journal:  Cancer Manag Res       Date:  2018-07-19       Impact factor: 3.989

View more
  3 in total

Review 1.  The Prognostic value of the Fibrinogen to pre-albumin ratio in malignant tumors of the digestive system: a systematic review and meta-analysis.

Authors:  Baibei Li; Huachu Deng; Ziyan Zhou; Bo Tang
Journal:  Cancer Cell Int       Date:  2022-01-15       Impact factor: 5.722

2.  Preoperative carcinoembryonic antigen to body mass index ratio contributes to prognosis prediction in colorectal cancer.

Authors:  Jia Xiang; Mengyao Ding; Jixing Lin; Tianhui Xue; Qianwen Ye; Bing Yan
Journal:  Oncol Lett       Date:  2022-09-29       Impact factor: 3.111

3.  Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer.

Authors:  Xiang Huang; Yu Huan; Long Liu; Qianwen Ye; Jian Guo; Bing Yan
Journal:  World J Surg Oncol       Date:  2022-09-24       Impact factor: 3.253

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.